PIM1 and pulmonary arterial hypertension: Since pipeline drug targets with human genetic evidence of disease association are more likely to lead to approved drugs than those without such evidence (Nelson et al., 2015; Hong, 2022), our study lends important support for PIM1 inhibition as a promising therapeutic approach for PAH.